Documentation

Press release

Datesort ascending Press release
27/03/2017 - 7:30 CET Inventiva: acceleration of the clinical development activities and consolidation of the financial position in 2016
17/03/2017 - 8:47 CET Inventiva Announces the Implementation of a Liquidity Contract with Oddo & Cie (only in french)
17/03/2017 - 8:30 CET Inventiva’s confirms the success of its IPO. Over-allotment option partially exercised
14/02/2017 - 8:13 CET Inventiva raises €48 million in a successful initial public offering on Euronext Paris
02/02/2017 - 7:14 CET Inventiva launches its initial public offering on the regulated market of Euronext Paris
13/01/2017 - 8:19 CET Inventiva files an update to its document de base with a view to its initial public offering
03/01/2017 - 16:30 CET Inventiva Announces Initiation of Phase IIb Clinical Trial of IVA337 for Treatment of Non-Alcoholic Steatohepatitis (NASH)
19/09/2016 - 19:10 CET Inventiva Announces Receipt of €2.3 million in Grant Funding for YAP/TEAD Protein Research Program
11/07/2016 - 10:30 CET Inventiva announces the registration of its IPO document de base
31/05/2016 - 10:40 CET Boehringer Ingelheim and Inventiva collaborate to develop potential new treatments for idiopathic pulmonary fibrosis
25/02/2016 - 18:33 CET Inventiva rewarded for its innovative approach with IVA337 at the 4th Systemic Sclerosis World Congress
28/01/2016 - 17:59 CET IVA337 delivers significant therapeutic advances in fibrosis, a major public health challenge
03/12/2015 - 10:05 CET European Eurostars funding received for epigenetics program NSD2
09/02/2015 - 12:49 CET SensiQ Technologies and Inventiva set up a European Center of Excellence in surface plasmon resonance (SPR) technologies
02/12/2014 - 15:56 CET Inventiva receives another positive opinion on orphan drug designation in the European Union for IVA337 – for Idiopathic Pulmonary Fibrosis
03/11/2014 - 13:33 CET Inventiva receives positive opinion on orphan drug designation in Systemic Sclerosis for IVA 337

Pages